Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-10-05

AUTHORS

Pratik Sinha, Kevin L. Delucchi, B. Taylor Thompson, Daniel F. McAuley, Michael A. Matthay, Carolyn S. Calfee

ABSTRACT

PurposeUsing latent class analysis (LCA), we have consistently identified two distinct subphenotypes in four randomized controlled trial cohorts of ARDS. One subphenotype has hyper-inflammatory characteristics and is associated with worse clinical outcomes. Further, within three negative clinical trials, we observed differential treatment response by subphenotype to randomly assigned interventions. The main purpose of this study was to identify ARDS subphenotypes in a contemporary NHLBI Network trial of infection-associated ARDS (SAILS) using LCA and to test for differential treatment response to rosuvastatin therapy in the subphenotypes.MethodsLCA models were constructed using a combination of biomarker and clinical data at baseline in the SAILS study (n = 745). LCA modeling was then repeated using an expanded set of clinical class-defining variables. Subphenotypes were tested for differential treatment response to rosuvastatin.ResultsThe two-class LCA model best fit the population. Forty percent of the patients were classified as the “hyper-inflammatory” subphenotype. Including additional clinical variables in the LCA models did not identify new classes. Mortality at day 60 and day 90 was higher in the hyper-inflammatory subphenotype. No differences in outcome were observed between hyper-inflammatory patients randomized to rosuvastatin therapy versus placebo.ConclusionsLCA using a two-subphenotype model best described the SAILS population. The subphenotypes have features consistent with those previously reported in four other cohorts. Addition of new class-defining variables in the LCA model did not yield additional subphenotypes. No treatment effect was observed with rosuvastatin. These findings further validate the presence of two subphenotypes and demonstrate their utility for patient stratification in ARDS. More... »

PAGES

1859-1869

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00134-018-5378-3

DOI

http://dx.doi.org/10.1007/s00134-018-5378-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1107429770

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30291376


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acute Lung Injury", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Latent Class Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Respiratory Distress Syndrome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rosuvastatin Calcium", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sepsis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, 505 Parnassus Ave, Box 0111, 94143-0111, San Francisco, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, 505 Parnassus Ave, Box 0111, 94143-0111, San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sinha", 
        "givenName": "Pratik", 
        "id": "sg:person.01011732634.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011732634.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Delucchi", 
        "givenName": "Kevin L.", 
        "id": "sg:person.01036655722.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036655722.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.32224.35", 
          "name": [
            "Department of Medicine, Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thompson", 
        "givenName": "B. Taylor", 
        "id": "sg:person.07544422077.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07544422077.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK", 
          "id": "http://www.grid.ac/institutes/grid.416232.0", 
          "name": [
            "Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen\u2019s University of Belfast, Belfast, UK", 
            "Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McAuley", 
        "givenName": "Daniel F.", 
        "id": "sg:person.013052706317.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013052706317.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, 505 Parnassus Ave, Box 0111, 94143-0111, San Francisco, CA, USA", 
            "Department of Anesthesia, University of California, San Francisco, San Francisco, CA, USA", 
            "Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matthay", 
        "givenName": "Michael A.", 
        "id": "sg:person.01066335761.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066335761.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, 505 Parnassus Ave, Box 0111, 94143-0111, San Francisco, CA, USA", 
            "Department of Anesthesia, University of California, San Francisco, San Francisco, CA, USA", 
            "Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Calfee", 
        "givenName": "Carolyn S.", 
        "id": "sg:person.01222460111.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222460111.09"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/cc8872", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007684107", 
          "https://doi.org/10.1186/cc8872"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1741-7015-7-34", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024284364", 
          "https://doi.org/10.1186/1741-7015-7-34"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12916-015-0368-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014024230", 
          "https://doi.org/10.1186/s12916-015-0368-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00134-006-0251-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029466900", 
          "https://doi.org/10.1007/s00134-006-0251-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/10898570-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010268448", 
          "https://doi.org/10.2165/10898570-000000000-00000"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-10-05", 
    "datePublishedReg": "2018-10-05", 
    "description": "PurposeUsing latent class analysis (LCA), we have consistently identified two distinct subphenotypes in four randomized controlled trial cohorts of ARDS. One subphenotype has hyper-inflammatory characteristics and is associated with worse clinical outcomes. Further, within three negative clinical trials, we observed differential treatment response by subphenotype to randomly assigned interventions. The main purpose of this study was to identify ARDS subphenotypes in a contemporary NHLBI Network trial of infection-associated ARDS (SAILS) using LCA and to test for differential treatment response to rosuvastatin therapy in the subphenotypes.MethodsLCA models were constructed using a combination of biomarker and clinical data at baseline in the SAILS study (n\u2009=\u2009745). LCA modeling was then repeated using an expanded set of clinical class-defining variables. Subphenotypes were tested for differential treatment response to rosuvastatin.ResultsThe two-class LCA model best fit the population. Forty percent of the patients were classified as the \u201chyper-inflammatory\u201d subphenotype. Including additional clinical variables in the LCA models did not identify new classes. Mortality at day 60 and day 90 was higher in the hyper-inflammatory subphenotype. No differences in outcome were observed between hyper-inflammatory patients randomized to rosuvastatin therapy versus placebo.ConclusionsLCA using a two-subphenotype model best described the SAILS population. The subphenotypes have features consistent with those previously reported in four other cohorts. Addition of new class-defining variables in the LCA model did not yield additional subphenotypes. No treatment effect was observed with rosuvastatin. These findings further validate the presence of two subphenotypes and demonstrate their utility for patient stratification in ARDS.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00134-018-5378-3", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2683958", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2784459", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.7211815", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.4899024", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.5475488", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1313639", 
        "issn": [
          "0342-4642", 
          "1432-1238"
        ], 
        "name": "Intensive Care Medicine", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "44"
      }
    ], 
    "keywords": [
      "differential treatment response", 
      "treatment response", 
      "ARDS subphenotypes", 
      "latent class analysis", 
      "worse clinical outcomes", 
      "additional clinical variables", 
      "combination of biomarkers", 
      "negative clinical trials", 
      "trial cohort", 
      "clinical outcomes", 
      "clinical variables", 
      "distinct subphenotypes", 
      "clinical trials", 
      "sepsis studies", 
      "clinical data", 
      "day 90", 
      "patient stratification", 
      "Network trial", 
      "secondary analysis", 
      "class analysis", 
      "ARDS", 
      "day 60", 
      "subphenotypes", 
      "SAiL study", 
      "treatment effects", 
      "patients", 
      "therapy", 
      "cohort", 
      "trials", 
      "outcomes", 
      "placebo", 
      "response", 
      "statins", 
      "lung", 
      "rosuvastatin", 
      "population", 
      "mortality", 
      "baseline", 
      "biomarkers", 
      "study", 
      "intervention", 
      "percent", 
      "stratification", 
      "findings", 
      "variables", 
      "differences", 
      "analysis", 
      "effect", 
      "utility", 
      "presence", 
      "combination", 
      "purpose", 
      "data", 
      "addition", 
      "model", 
      "new class", 
      "features", 
      "characteristics", 
      "LCA model", 
      "main purpose", 
      "class", 
      "ConclusionsLCA", 
      "set", 
      "modeling", 
      "LCA modeling"
    ], 
    "name": "Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study", 
    "pagination": "1859-1869", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1107429770"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00134-018-5378-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30291376"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00134-018-5378-3", 
      "https://app.dimensions.ai/details/publication/pub.1107429770"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:37", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_756.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00134-018-5378-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00134-018-5378-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00134-018-5378-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00134-018-5378-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00134-018-5378-3'


 

This table displays all metadata directly associated to this object as RDF triples.

259 TRIPLES      21 PREDICATES      109 URIs      96 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00134-018-5378-3 schema:about N1ffdf77f5d14485daed22c4bc01552f0
2 N6d6113a5e22546e383c6313653eddd51
3 N790fab7dcc174e75951dab039fc7ce1e
4 N9be248e800b94666a2a4600f2224dac9
5 Na5bcddbcda9a4e97ae73d6b6705d6329
6 Nb0a7483289b944e6b119c21803d7e806
7 Nb31b43dde0e14590a017b6caff584091
8 Nc5d66796b88c4a21838780411b66a0d8
9 Ne5da67d39d884fea866ecd622e819d75
10 Nedc80422d7de469f9c0860b53e4d5812
11 Nedde7e8045804e57800f82fe4863d893
12 Nf5af31d9aeb24d378fd7b671eda5e14d
13 Nf6da15d36e884dcb9402c318a35495f1
14 Nfa444927135f45edb8c8a94792800bc5
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author N9672783f82dc48b68fe0e8058f0377c3
18 schema:citation sg:pub.10.1007/s00134-006-0251-1
19 sg:pub.10.1186/1741-7015-7-34
20 sg:pub.10.1186/cc8872
21 sg:pub.10.1186/s12916-015-0368-6
22 sg:pub.10.2165/10898570-000000000-00000
23 schema:datePublished 2018-10-05
24 schema:datePublishedReg 2018-10-05
25 schema:description PurposeUsing latent class analysis (LCA), we have consistently identified two distinct subphenotypes in four randomized controlled trial cohorts of ARDS. One subphenotype has hyper-inflammatory characteristics and is associated with worse clinical outcomes. Further, within three negative clinical trials, we observed differential treatment response by subphenotype to randomly assigned interventions. The main purpose of this study was to identify ARDS subphenotypes in a contemporary NHLBI Network trial of infection-associated ARDS (SAILS) using LCA and to test for differential treatment response to rosuvastatin therapy in the subphenotypes.MethodsLCA models were constructed using a combination of biomarker and clinical data at baseline in the SAILS study (n = 745). LCA modeling was then repeated using an expanded set of clinical class-defining variables. Subphenotypes were tested for differential treatment response to rosuvastatin.ResultsThe two-class LCA model best fit the population. Forty percent of the patients were classified as the “hyper-inflammatory” subphenotype. Including additional clinical variables in the LCA models did not identify new classes. Mortality at day 60 and day 90 was higher in the hyper-inflammatory subphenotype. No differences in outcome were observed between hyper-inflammatory patients randomized to rosuvastatin therapy versus placebo.ConclusionsLCA using a two-subphenotype model best described the SAILS population. The subphenotypes have features consistent with those previously reported in four other cohorts. Addition of new class-defining variables in the LCA model did not yield additional subphenotypes. No treatment effect was observed with rosuvastatin. These findings further validate the presence of two subphenotypes and demonstrate their utility for patient stratification in ARDS.
26 schema:genre article
27 schema:isAccessibleForFree true
28 schema:isPartOf N7bfe3debdc364bb195ce46b481e51a0c
29 N8975329ea19f498aa10cfb0bf6ae0acb
30 sg:journal.1313639
31 schema:keywords ARDS
32 ARDS subphenotypes
33 ConclusionsLCA
34 LCA model
35 LCA modeling
36 Network trial
37 SAiL study
38 addition
39 additional clinical variables
40 analysis
41 baseline
42 biomarkers
43 characteristics
44 class
45 class analysis
46 clinical data
47 clinical outcomes
48 clinical trials
49 clinical variables
50 cohort
51 combination
52 combination of biomarkers
53 data
54 day 60
55 day 90
56 differences
57 differential treatment response
58 distinct subphenotypes
59 effect
60 features
61 findings
62 intervention
63 latent class analysis
64 lung
65 main purpose
66 model
67 modeling
68 mortality
69 negative clinical trials
70 new class
71 outcomes
72 patient stratification
73 patients
74 percent
75 placebo
76 population
77 presence
78 purpose
79 response
80 rosuvastatin
81 secondary analysis
82 sepsis studies
83 set
84 statins
85 stratification
86 study
87 subphenotypes
88 therapy
89 treatment effects
90 treatment response
91 trial cohort
92 trials
93 utility
94 variables
95 worse clinical outcomes
96 schema:name Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study
97 schema:pagination 1859-1869
98 schema:productId Nb4e4a4ffd082443ea274cfb214808a3d
99 Nc0ccf3c2fb0b4d84a979a46b1a5f87b2
100 Nce8ed911b7b34bdaad8f897ba19492f9
101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107429770
102 https://doi.org/10.1007/s00134-018-5378-3
103 schema:sdDatePublished 2022-12-01T06:37
104 schema:sdLicense https://scigraph.springernature.com/explorer/license/
105 schema:sdPublisher N80320ed276984938a250a3ca033bb28a
106 schema:url https://doi.org/10.1007/s00134-018-5378-3
107 sgo:license sg:explorer/license/
108 sgo:sdDataset articles
109 rdf:type schema:ScholarlyArticle
110 N1ffdf77f5d14485daed22c4bc01552f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Cohort Studies
112 rdf:type schema:DefinedTerm
113 N6d6113a5e22546e383c6313653eddd51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Adult
115 rdf:type schema:DefinedTerm
116 N767804c0d7cd4d97af631ec63ec493c1 rdf:first sg:person.013052706317.18
117 rdf:rest Nf18b9e58dfc94f90a325133c7b0ad5ac
118 N790fab7dcc174e75951dab039fc7ce1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Survival Rate
120 rdf:type schema:DefinedTerm
121 N7bfe3debdc364bb195ce46b481e51a0c schema:volumeNumber 44
122 rdf:type schema:PublicationVolume
123 N80320ed276984938a250a3ca033bb28a schema:name Springer Nature - SN SciGraph project
124 rdf:type schema:Organization
125 N8975329ea19f498aa10cfb0bf6ae0acb schema:issueNumber 11
126 rdf:type schema:PublicationIssue
127 N8f4c4e32df1f4dcdac981c800cfe8d23 rdf:first sg:person.01222460111.09
128 rdf:rest rdf:nil
129 N9672783f82dc48b68fe0e8058f0377c3 rdf:first sg:person.01011732634.45
130 rdf:rest Nd6290f7a4ff749db858f47795f48dea0
131 N9be248e800b94666a2a4600f2224dac9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Hydroxymethylglutaryl-CoA Reductase Inhibitors
133 rdf:type schema:DefinedTerm
134 Na266f750d3f5419eb486377368148097 rdf:first sg:person.07544422077.04
135 rdf:rest N767804c0d7cd4d97af631ec63ec493c1
136 Na5bcddbcda9a4e97ae73d6b6705d6329 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Acute Lung Injury
138 rdf:type schema:DefinedTerm
139 Nb0a7483289b944e6b119c21803d7e806 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Middle Aged
141 rdf:type schema:DefinedTerm
142 Nb31b43dde0e14590a017b6caff584091 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Humans
144 rdf:type schema:DefinedTerm
145 Nb4e4a4ffd082443ea274cfb214808a3d schema:name pubmed_id
146 schema:value 30291376
147 rdf:type schema:PropertyValue
148 Nc0ccf3c2fb0b4d84a979a46b1a5f87b2 schema:name doi
149 schema:value 10.1007/s00134-018-5378-3
150 rdf:type schema:PropertyValue
151 Nc5d66796b88c4a21838780411b66a0d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Respiratory Distress Syndrome
153 rdf:type schema:DefinedTerm
154 Nce8ed911b7b34bdaad8f897ba19492f9 schema:name dimensions_id
155 schema:value pub.1107429770
156 rdf:type schema:PropertyValue
157 Nd6290f7a4ff749db858f47795f48dea0 rdf:first sg:person.01036655722.84
158 rdf:rest Na266f750d3f5419eb486377368148097
159 Ne5da67d39d884fea866ecd622e819d75 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Male
161 rdf:type schema:DefinedTerm
162 Nedc80422d7de469f9c0860b53e4d5812 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Aged
164 rdf:type schema:DefinedTerm
165 Nedde7e8045804e57800f82fe4863d893 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Female
167 rdf:type schema:DefinedTerm
168 Nf18b9e58dfc94f90a325133c7b0ad5ac rdf:first sg:person.01066335761.54
169 rdf:rest N8f4c4e32df1f4dcdac981c800cfe8d23
170 Nf5af31d9aeb24d378fd7b671eda5e14d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Rosuvastatin Calcium
172 rdf:type schema:DefinedTerm
173 Nf6da15d36e884dcb9402c318a35495f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Sepsis
175 rdf:type schema:DefinedTerm
176 Nfa444927135f45edb8c8a94792800bc5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Latent Class Analysis
178 rdf:type schema:DefinedTerm
179 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
180 schema:name Medical and Health Sciences
181 rdf:type schema:DefinedTerm
182 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
183 schema:name Clinical Sciences
184 rdf:type schema:DefinedTerm
185 sg:grant.2683958 http://pending.schema.org/fundedItem sg:pub.10.1007/s00134-018-5378-3
186 rdf:type schema:MonetaryGrant
187 sg:grant.2784459 http://pending.schema.org/fundedItem sg:pub.10.1007/s00134-018-5378-3
188 rdf:type schema:MonetaryGrant
189 sg:grant.4899024 http://pending.schema.org/fundedItem sg:pub.10.1007/s00134-018-5378-3
190 rdf:type schema:MonetaryGrant
191 sg:grant.5475488 http://pending.schema.org/fundedItem sg:pub.10.1007/s00134-018-5378-3
192 rdf:type schema:MonetaryGrant
193 sg:grant.7211815 http://pending.schema.org/fundedItem sg:pub.10.1007/s00134-018-5378-3
194 rdf:type schema:MonetaryGrant
195 sg:journal.1313639 schema:issn 0342-4642
196 1432-1238
197 schema:name Intensive Care Medicine
198 schema:publisher Springer Nature
199 rdf:type schema:Periodical
200 sg:person.01011732634.45 schema:affiliation grid-institutes:grid.266102.1
201 schema:familyName Sinha
202 schema:givenName Pratik
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011732634.45
204 rdf:type schema:Person
205 sg:person.01036655722.84 schema:affiliation grid-institutes:grid.266102.1
206 schema:familyName Delucchi
207 schema:givenName Kevin L.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036655722.84
209 rdf:type schema:Person
210 sg:person.01066335761.54 schema:affiliation grid-institutes:grid.266102.1
211 schema:familyName Matthay
212 schema:givenName Michael A.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066335761.54
214 rdf:type schema:Person
215 sg:person.01222460111.09 schema:affiliation grid-institutes:grid.266102.1
216 schema:familyName Calfee
217 schema:givenName Carolyn S.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222460111.09
219 rdf:type schema:Person
220 sg:person.013052706317.18 schema:affiliation grid-institutes:grid.416232.0
221 schema:familyName McAuley
222 schema:givenName Daniel F.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013052706317.18
224 rdf:type schema:Person
225 sg:person.07544422077.04 schema:affiliation grid-institutes:grid.32224.35
226 schema:familyName Thompson
227 schema:givenName B. Taylor
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07544422077.04
229 rdf:type schema:Person
230 sg:pub.10.1007/s00134-006-0251-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029466900
231 https://doi.org/10.1007/s00134-006-0251-1
232 rdf:type schema:CreativeWork
233 sg:pub.10.1186/1741-7015-7-34 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024284364
234 https://doi.org/10.1186/1741-7015-7-34
235 rdf:type schema:CreativeWork
236 sg:pub.10.1186/cc8872 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007684107
237 https://doi.org/10.1186/cc8872
238 rdf:type schema:CreativeWork
239 sg:pub.10.1186/s12916-015-0368-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014024230
240 https://doi.org/10.1186/s12916-015-0368-6
241 rdf:type schema:CreativeWork
242 sg:pub.10.2165/10898570-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010268448
243 https://doi.org/10.2165/10898570-000000000-00000
244 rdf:type schema:CreativeWork
245 grid-institutes:grid.266102.1 schema:alternateName Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA
246 Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, 505 Parnassus Ave, Box 0111, 94143-0111, San Francisco, CA, USA
247 Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA
248 schema:name Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA
249 Department of Anesthesia, University of California, San Francisco, San Francisco, CA, USA
250 Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, 505 Parnassus Ave, Box 0111, 94143-0111, San Francisco, CA, USA
251 Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA
252 rdf:type schema:Organization
253 grid-institutes:grid.32224.35 schema:alternateName Department of Medicine, Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA, USA
254 schema:name Department of Medicine, Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA, USA
255 rdf:type schema:Organization
256 grid-institutes:grid.416232.0 schema:alternateName Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK
257 schema:name Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University of Belfast, Belfast, UK
258 Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK
259 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...